Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Camrelizumab +/- SBRT in Nasopharyngeal Carcinoma
NCT04830267Phase 2Recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Mar 2021
- Primary completion
- Aug 2024
- Modality
- Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of camrelizumab in nasopharyngeal carcinoma (NPC), sponsored by Chongqing University Cancer Hospital. Started Mar 2021; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT04830267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04830267.